Protein Switch Dictates Cellular Fate: Stem Cell or Neuron

Contact Information

Available for logged-in reporters only

Newswise Researchers at the University of California, San Diego School of Medicine have discovered that a well-known protein has a new function: It acts in a biological circuit to determine whether an immature neural cell remains in a stem-like state or proceeds to become a functional neuron.

The findings, published in the February 13 online issue of Cell Reports, more fully illuminate a fundamental but still poorly understood cellular act and may have significant implications for future development of new therapies for specific neurological disorders, including autism and schizophrenia.

Postdoctoral fellow Chih-Hong Lou, working with principal investigator Miles F. Wilkinson, PhD, professor in the Department of Reproductive Medicine and a member of the UC San Diego Institute for Genomic Medicine, and other colleagues, discovered that this critical biological decision is controlled by UPF1, a protein essential for the nonsense-mediated RNA decay (NMD) pathway.

NMD was previously established to have two broad roles. First, it is a quality control mechanism used by cells to eliminate faulty messenger RNA (mRNA) molecules that help transcribe genetic information into the construction of proteins essential to life. Second, it degrades a specific group of normal mRNAs. The latter function of NMD has been hypothesized to be physiologically important, but until now it had not been clear whether this is the case.

Wilkinson and colleagues discovered that in concert with a special class of RNAs called microRNA, UPF1 acts as a molecular switch to determine when immature (non-functional) neural cells differentiate into non-dividing (functional) neurons. Specifically, UPF1 triggers the decay of a particular mRNA that encodes for a protein in the TGF- signaling pathway that promotes neural differentiation. By degrading that mRNA, the encoded protein fails to be produced and neural differentiation is prevented. Thus, Lou and colleagues identified for the first time a molecular circuit in which NMD acts to drive a normal biological response.

NMD also promotes the decay of mRNAs encoding proliferation inhibitors, which Wilkinson said may explain why NMD stimulates the proliferative state characteristic of stem cells.

There are many potential clinical ramifications for these findings, Wilkinson said. One is that by promoting the stem-like state, NMD may be useful for reprogramming differentiated cells into stem cells more efficiently.

Another implication follows from the finding that NMD is vital to the normal development of the brain in diverse species, including humans. Humans with deficiencies in NMD have intellectual disability and often also have schizophrenia and autism. Therapies to enhance NMD in affected individuals could be useful in restoring the correct balance of stem cells and differentiated neurons and thereby help restore normal brain function.

Visit link:
Protein Switch Dictates Cellular Fate: Stem Cell or Neuron

Total Recovery Lecture Series: Novel Treatments for Joint, Tendon & Ligament Pain, Part 3 – Video


Total Recovery Lecture Series: Novel Treatments for Joint, Tendon Ligament Pain, Part 3
Part 3: Regenerative Therapies: Prolotherapy, Platelet Rich Plasma (PRP) and Stem Cell Therapy Dr. David Wang, Harvard trained and Board Certified in Physica...

By: KaplanCenter

See more here:
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon & Ligament Pain, Part 3 - Video

Global Stem Cells, Inc., Bioheart, Inc., and Paul Perito …

Miami, FL (PRWEB) February 11, 2014

Global Stem Cells Group, Bioheart, Inc., and Paul Perito Urology announce plans to launch stem cell clinical trials for treatment of Erectile Dysfunction (ED).

Paul Perito, M.D. of Perito Urology in Coral Gables, Florida and the principal investigator of the trial study, titled, "An Open-label, Non-randomized, Single-center Study to Assess the Safety and Effects of Autologous Adipose-derived Stromal Cells Delivered into the Corpus Cavernosum in Patients with Erectile Dysfunction," aims to assess the safety and efficacy of stem cell implantation therapy in patients with ED.

The cell therapy in this study will be composed of stem cells derived from a patients own adipose (fat) tissue, harvested by syringe liposuction. The adipose stem cells will then be delivered into the corpus cavernosum of the penis.

Clinical trials will be held at Perito Urology, in cooperation with Global Stem Cells Group and Bioheart. Up to 20 patients will be enrolled.

Fort Myers Florida-based Emcyte Corporation, a leading provider of biotechnology products for platelet rich plasma and bone marrow concentrate grafting procedures, will be providing systems and kits to be used in the trial.

To learn more about Global Stem Cells Group's clinical trials, and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

View original post here:
Global Stem Cells, Inc., Bioheart, Inc., and Paul Perito ...

Miami Stem Cell Treatment Center Educational Seminar: Adipose-Derived Stem Cells, Public Lecture

Boca Raton, FL (PRWEB) February 12, 2014

The Miami Stem Cell Treatment Center, PC, located in Miami, Ft. Lauderdale, and Boca Raton, Florida, announces a series of free public seminars on the use of stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief, and, Dr. Nia Smyrniotis, Medical Director.

The seminars will be held on February 16th and March 2nd. On February 16th, the seminar will be held at the Marriott Boca Raton, at Boca Center, 5150 Town Center Circle, Boca Raton, Florida 33486, at 2pm; and on March 2nd at the Hampton Inn Fort Lauderdale Downtown, 250 N. Andrews Blvd., Fort Lauderdale, Florida 33301, at 2pm. You can also join Miami Stem Cell Treatment Center at the Health and Wellness Experience Expo presented by WPEC Channel 12 and the Sun-Sentinel on March 1st at Mizner Park Amphitheater, Boca Raton, Florida from 10am-5pm. No reservations required.

At the Miami Stem Cell Treatment Center, utilizing investigational protocols, adult adipose derived stem cells (ADSCs) can be deployed to improve patients quality of life with a number of degenerative conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (also called stromal vascular fraction (SVF)). Adipose tissue is exceptionally abundant in ADSCs. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body's natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys damaged cells. The Miami Stem Cell Treatment Center only uses autologous stem cells from a person's own fat no embryonic stem cells are used. Our current areas of study include: Heart Failure, Emphysema, COPD, Asthma, Parkinsons Disease, Stroke, Multiple Sclerosis, and orthopedic joint injections. For more information, or if someone thinks they may be a candidate for one of the stem cell protocols offered by Miami Stem Cell Treatment Center, they may contact Dr. Nia or Dr. Gionis directly at (561) 331-2999, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com.

About Miami Stem Cell Treatment Center:

The Miami Stem Cell Treatment Center is an affiliate of the Irvine Stem Cell Treatment Center (Irvine, California) and the Cell Surgical Network (CSN). We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Research Protections; and the study is registered with http://www.Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information contact: Miami(at)MiamiStemCellsUSA(dot)com or visit our website: http://www.MiamiStemCellsUSA.com.

Go here to see the original:
Miami Stem Cell Treatment Center Educational Seminar: Adipose-Derived Stem Cells, Public Lecture

Vet-Stem, Inc. and Petplan Work Together in the New Year to Bring Regenerative Cell Therapies to Pets

Poway, California (PRWEB) February 13, 2014

The leading Regenerative Veterinary Medicine company, Vet-Stem, Inc., and Americas best-loved pet insurer, Petplan, are working together to bring stem cell therapy and other regenerative cell therapies to pets nationwide. Stem cell therapy by Vet-Stem has been available for pets like dogs and cats for the last decade and covered by Petplan since 2010.

Founded in 2003 by Chris and Natasha Ashton, Petplan was recently named to Forbes magazines annual ranking of Americas Most Promising Companies for the second year in a row, and is rated one of the top pet insurance companies by Consumer Advocate and Canine Journal. Petplan proudly offers life-long coverage for hereditary and chronic conditions as well as alternative treatments, like stem cell therapy, as standard.

Our core value is that pets come first, and that starts with our comprehensive plans. So, were excited to see so many of our policyholders start to take advantage of cutting-edge treatments like Vet-Stem Regenerative Cell Therapy. Our team thrives on being able to provide coverage for the best and most up-to-date treatment modalities for the pets in our Petplan family, so hearing great stories about stem cell therapy from our policyholders is a real boost for us! - Dr. Jules Benson, Vice President of Veterinary Services at Petplan

Current uses of stem cell therapy are treating the pain and inflammation from arthritis and to repair orthopedic injuries. According to veterinarians, greater than 80% of dogs showed an improved quality of life after stem cell therapy. At 90 days post-treatment, more than 33% of dogs discontinued use of non-steroidal anti-inflammatory drugs (NSAIDs) completely, with an additional 28% decreasing their usage.

I started Vet-Stem in order to help horses with career-ending injuries to their tendons and ligaments, but so many more animals have been saved from a life of pain or even from euthanasia. I feel privileged and excited to be a part of this therapy that has changed how veterinary medicine is practiced, as well as contributing to changes in human medicine, - Robert Harman, DVM, CEO, Vet-Stem, Inc.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

See original here:
Vet-Stem, Inc. and Petplan Work Together in the New Year to Bring Regenerative Cell Therapies to Pets

Cancer researchers discover pre-leukemic stem cell at root of AML, relapse

Cancer researchers led by stem cell scientist Dr. John Dick have discovered a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML).

The research, published online today in Nature is a significant leap in understanding the steps that a normal cell has to go through as it turns into AML, says Dr. Dick, and sets the stage to advance personalized cancer medicine by potentially identifying individuals who might benefit from targeting the pre-leukemic stem cell. AML is an aggressive blood cancer that the new research shows starts in stem cells in the bone marrow. Dr. Dick, a Senior Scientist at Princess Margaret Cancer Centre, University Health Network (UHN), and Professor in the Department of Molecular Genetics, University of Toronto, pioneered the cancer stem cell field by first identifying leukemia stem cells (1994) and colon cancer stem cells (2007).

"Our discovery lays the groundwork to detect and target the pre-leukemic stem cell and thereby potentially stop the disease at a very early stage when it may be more amenable to treatment," says Dr. Dick, who holds a Canada Research Chair in Stem Cell Biology and is also Director of the Cancer Stem Cell Program at the Ontario Institute for Cancer Research (OICR).

"Now we have a potential tool for earlier diagnosis that may allow early intervention before the development of full AML. We can also monitor remission and initiate therapy to target the pre-leukemic stem cell to prevent relapse," he says.

The findings show that in about 25% of AML patients, a mutation in the gene DNMT3a causes pre-leukemic stem cells to develop that function like normal blood stem cells but grow abnormally. These cells survive chemotherapy and can be found in the bone marrow at remission, forming a reservoir of cells that may eventually acquire additional mutations, leading to relapse.

The discovery of pre-leukemic stem cells came out of a large Leukemia Disease Team that Dr. Dick assembled and included oncologists who collected samples for the Princess Margaret Cancer Centre Biobank and genome scientists at the OICR who developed sophisticated targeted sequencing methodology. With this team, it was possible to carry out genomic analysis of more than 100 leukemia genes on many patient samples. The findings also capitalized on data from more than six years of experiments in Dr. Dick's lab involving growing human AML in special mice that do not reject human cells.

"By peering into the black box of how cancer develops during the months and years prior to when it is first diagnosed, we have demonstrated a unique finding. People tend to think relapse after remission means chemotherapy didn't kill all the cancer cells. Our study suggests that in some cases the chemotherapy does, in fact, eradicate AML; what it does not touch are the pre-leukemic stem cells that can trigger another round of AML development and ultimately disease relapse," says Dr. Dick, who anticipates the findings will spawn accelerated drug development to specifically target DNMT3a.

These findings should also provide impetus for researchers to look for pre-cancerous cells in AML patients with other mutations and even in non-blood cancers.

Dr. Dick is also renowned for isolating a human blood stem cell in its purest form (2011) -- as a single stem cell capable of regenerating the entire blood system. He is a Senior Scientist at UHN's McEwen Centre for Regenerative Medicine and co-leader of a Cancer Stem Cell Consortium (CSCC)-funded research project HALT (Highly Active Anti-Leukemia Stem Cell Therapy), which is a partnership between CSCC and the California Institute for Regenerative Medicine.

For more than 20 years, Dr. Dick's research has focused on understanding the cellular processes that maintain tumour growth by investigating the complexities and interplay among genetic and non-genetic determinants of cancer. His research follows on the original 1961 discovery of the blood stem cell by Princess Margaret Cancer Centre (formerly Ontario Cancer Institute) scientists Dr. James Till and the late Dr. Ernest McCulloch, which formed the basis of all current stem cell research.

Continued here:
Cancer researchers discover pre-leukemic stem cell at root of AML, relapse

Stem cells from baby's umbilical cord save life of granddad given months to live

Patients with leukaemia need stem cells to replace damaged ones - the blood in the umbilical cord is so immature the recipient can accept the cells more easily

A grandad given just months to live has beaten leukaemia after getting stem cells from two babies umbilical cords.

The move was the only option to save David Pyne, 60, after all other treatments failed. He was one of the first to have the procedure.

He said of the stem cell transplant: To think two newborns saved an old mans life is just marvellous and its given me more time with my own grandchildren.

The dad-of-four was diagnosed with cancer in August 2012 and had chemotherapy and blood transfusions.

He desperately needed a stem cell donor but a match could not be found and he was given just 12 to 18 months to live.

But then he was offered cells from the umbilical cords of one baby in America and another in France.

He said: Things were looking pretty grim until I got the news about the possibility of an umbilical cord stem cell transplant.

The team found two separate umbilical cord donors that were a good match.

"I felt elated.

See more here:
Stem cells from baby's umbilical cord save life of granddad given months to live

Top Henderson Pain Management Clinic, Nevada Pain, Now Offering Over 25 Effective Pain Treatments

Henderson, NV (PRWEB) February 12, 2014

The top pain management clinic in Henderson, Nevada Pain, is now offering over 25 effective pain treatments. The options include both medical and interventional pain management, chiropractic, physical therapy, spinal decompression therapy, stem cell treatments and acupuncture. Call (702) 323-0553 for more information and scheduling.

Nevada Pain's Board Certified team provides patients with customized options for treatment with comprehensive options. With over a third of Americans suffering from chronic pain, it is vital to have extensive options for achieving relief. With over 25 options to choose from, the success rate at Nevada Pain for avoiding surgery and providing patients relief is over 95%!

Treatments include both medical and interventional with oral or topical NSAIDS, neuropathic medicines, pain medication, muscle relaxers and more. Several types of epidural injections are provided: radiofrequency ablation, spinal cord stimulator implants, stem cell injections and all types of joint injections.

Chiropractic and physical therapy is offered in addition to spinal decompression therapy and acupuncture. The combination of traditional and alternative Las Vegas pain management therapies provides an excellent chance for the best patient success.

Both simple and complex conditions are treated such as arthritis, sciatica, spinal stenosis, scoliosis, fibromyalgia, headaches, migraines, neuropathy, degenerative disc disease and failed back or neck surgery. Nevada Pain does not believe in a "one size fits all" approach.

For more information and scheduling with pain management Henderson NV trusts, call (702) 323-0553.

Visit link:
Top Henderson Pain Management Clinic, Nevada Pain, Now Offering Over 25 Effective Pain Treatments

New stem-cell method offers another alternative to embryonic research

Baltimore

A new method of creating versatile stem cells from a relatively simple manipulation of existing cells could further reduce the need for any stem-cell research involving human embryos, according to leading ethicists.

Although the process has only been tested in mice, two studies published Jan. 29 in the journal Nature detailed research showing success with a process called stimulus-triggered acquisition of pluripotency, or STAP.

Scientists from Japan's RIKEN research institute and Harvard's Brigham and Women's Hospital in Boston were able to reprogram blood cells from newborn mice by placing them in a low-level acidic bath for 30 minutes. Seven to 9 percent of the cells subjected to such stress returned to a state of pluripotency and were able to grow into other types of cells in the body.

"If this technology proves feasible with human cells, which seems likely, it will offer yet another alternative for obtaining highly flexible stem cells without relying on the destructive use of human embryos," said Fr. Tadeusz Pacholczyk, director of education at the National Catholic Bioethics Center in Philadelphia. "This is clearly a positive direction for scientific research."

Pacholczyk, a priest of the diocese of Fall River, Mass., who holds a doctorate in neuroscience from Yale University, said the only "potential future ethical issue" raised by the new STAP cells would be if scientists were to coax them into "a new degree of flexibility beyond classical pluripotency," creating cells "with essential characteristics of embryos and the propensity to develop into the adult organism."

"Generating human embryos in the laboratory, regardless of the specific methodology, will always raise significant ethical red flags," he said.

The Catholic church opposes any research involving the destruction of human embryos to create stem cells.

Richard Doerflinger, associate director of the U.S. bishops' Secretariat for Pro-Life Activities, said if the new method were used to create stem cells so versatile that they could form placenta tissue and make human cloning easier, "then we would have serious moral problems with that." But there is no indication so far that the scientists could or would do so, he added.

"You could misuse any powerful technology, but the technique itself is not problematic" in terms of Catholic teaching, Doerflinger said.

See the article here:
New stem-cell method offers another alternative to embryonic research